GRAL

Business Context and Reporting Period

Company: GRAIL, Inc. (GRAL)
Filing Type: Form 10-Q
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: GRAIL is a commercial-stage healthcare company focused on multi-cancer early detection (MCED) via its Galleri blood test. The company operates as a standalone public entity following its spin-off from Illumina, Inc. in June 2024. It is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Note: The filing does not provide a specific "Gross Margin" percentage, but reports a GAAP Gross Loss of $(13.7) million for Q3 2025 and $(51.4) million for 9M 2025. Adjusted Gross Profit (non-GAAP) was $20.0 million for Q3 2025 and $50.4 million for 9M 2025.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 26% year-over-year in Q3 2025 ($36.2M vs. $28.7M) and 19% for the nine-month period ($103.6M vs. $87.3M). Screening revenue grew 29% in Q3, driven by a 39% increase in Galleri sales volume, partially offset by a 7% decrease in average selling price (ASP).
• Expense Reduction: Operating expenses decreased significantly due to a restructuring plan initiated in late 2024.
  • R&D: Decreased 38% in Q3 ($48.6M vs. $78.2M) and 46% for 9M ($148.9M vs. $274.1M), driven by workforce reductions and completion of certain clinical study enrollments.
  • Sales & Marketing: Decreased 28% in Q3 ($25.5M vs. $35.6M) and 28% for 9M ($89.0M vs. $123.4M).
  • G&A: Decreased 21% in Q3 ($37.4M vs. $47.4M) and 30% for 9M ($120.4M vs. $171.7M), largely due to the cessation of legal fees related to the Illumina spin-off and hold-separate compliance.
• Impairment Charges: Goodwill and intangible asset impairment was $0 in Q3 2025 and $28.0 million for 9M 2025, a significant decrease from $1.42 billion in the prior year period (9M 2024), which included a massive impairment charge related to the spin-off.
• Liquidity: Cash and cash equivalents decreased from $214.2 million at year-end 2024 to $126.9 million at September 30, 2025, primarily due to operating cash outflows, though short-term marketable securities remained substantial at $413.2 million.

Guidance, Outlook, and Risks

• Strategic Partnerships & Financing:
  • Samsung: Entered a stock purchase agreement for a $110 million investment (subject to closing conditions by Jan 31, 2026) to commercialize Galleri in Korea and potentially other Asian markets.
  • Private Placement: Completed a $325 million private placement on October 21, 2025, to fund commercial activities and working capital.
• Regulatory Outlook: Plans to submit a Premarket Approval (PMA) application to the FDA in Q1 2026, utilizing data from the NHS-Galleri Trial and PATHFINDER 2 study. The company is navigating regulatory uncertainty regarding Laboratory Developed Tests (LDTs) following a federal court decision vacating the FDA's LDT Final Rule.
• Restructuring: The restructuring plan is substantially complete, with no remaining restructuring liability as of September 30, 2025. The company expects R&D expenses to decrease over the next three years as it focuses on Galleri and reduces investment in other programs (e.g., DAC, MRD).
• Risks:
  • Reimbursement: Galleri is not broadly reimbursed by Medicare or large commercial insurers; success depends on securing coverage.
  • Competition: New MCED products entered the market in late 2025, increasing competitive pressure.
  • Regulatory: Uncertainty regarding FDA authority over LDTs and the timeline for PMA approval.
  • Going Concern: While management believes current liquidity is sufficient for 12+ months, the company expects to continue incurring operating losses and may require additional financing.

Investor Verification Checklist

• Closing of Samsung Investment: Verify the satisfaction of closing conditions (including CFIUS approval and execution of collaboration agreements) by January 31, 2026, to confirm the $110 million proceeds.
• PMA Submission Timeline: Monitor the Q1 2026 FDA PMA submission date and any potential delays related to bridging studies or regulatory feedback.
• Reimbursement Progress: Track developments in Medicare coverage decisions and private payer contracts, as broad reimbursement is critical for long-term profitability.
• Intangible Asset Valuation: Review future impairment tests for the remaining $1.88 billion in finite-lived intangible assets (developed technology and trade names), which are amortized over 9-18 years.
• Operational Metrics: Monitor test volume growth versus ASP trends to ensure revenue growth is not solely volume-driven at the expense of margin.